Singapore – A new research study led by A*STAR.Singapore Immunology Network (A*STAR.SIgN) has found that neutrophils—one of the most abundant white blood cells in our body—change drastically in certain cancers, adopting a new function whereby they promote tumour growth. By carefully studying neutrophils as soon as they enter the tumour,...
Latest News
SINGAPORE – An international study has discovered that people living with the neurodegenerative condition Spinal Muscular Atrophy (SMA) are at higher risk of developing fatty liver disease, suggesting that SMA patients may face additional health problems over time. This finding raises significant concerns about long-term care and health outcomes for...
Göttingen, Germany – In the journal “Science Translational Medicine”, scientists from DZNE and LMU Hospital report on new insights into the mechanisms of “Niemann-Pick type C” (NPC), a rare neurodegenerative disease associated with dementia that can manifest as early as childhood. Their findings, based on studies in mice, cell cultures...
PLYMOUTH MEETING, Pennsylvania — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—today published its first ever set of treatment recommendations pertaining to neuroblastoma. Neuroblastoma is a type of solid tumor cancer that typically occurs in early childhood, with the majority diagnosed before age five. Neuroblastoma is the...
Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML Phase 1b data show low rate of differentiation syndrome and no cardiac safety signal of QTc prolongation MILAN, Italy — Johnson & Johnson (NYSE: JNJ) today announced...
RIVERSIDE, Calif. — Imagine if we could inhale scents that delay the onset of cancer, inflammation, or neurodegenerative disease. Researchers at the University of California, Riverside, are poised to bring this futuristic technology closer to reality. In lab experiments, a team led by Anandasankar Ray, a professor of molecular, cell and systems...
PASADENA, Calif. — LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, announced today publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical...
Boston, Mass. – Sickle cell disease, while rare, is the most common inherited blood disorder and affects over 100,000 people in the United States, more than 90% of whom are Black according to the Centers for Disease Control and Prevention. Although a medication called hydroxyurea can alleviate pain and lower...
Villejuif, France – Aglaia Therapeutics, a biotechnology startup developing promising new therapies that can overcome resistance to current targeted therapies in cancer patients, today announces the successful completion of a €4M ($4.7M) seed funding round. Advent France Biotechnology (AFB) led the round, with the participation of Crédit Mutuel Innovation and Pierre Fabre. AFB also acted...
LOS ANGELES, Calif. — A clinical trial from Keck Medicine of USC aims to provide a surgical solution for patients with a form of advanced pancreatic cancer previously considered inoperable. The study will investigate if chemotherapy followed by a novel type of surgery to remove the cancer is a safe...